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Viral vectors such as adenovirus have successful applications in vaccines and gene therapy 13 
but the manufacture of high quality virus remains a challenge. It is desirable to use the 14 
adsorption based chromatographic separations that so effectively underpin therapeutic 15 
protein manufacture. However fundamental differences in the size and stability of this class 16 
of product means it is necessary to revisit the design of sorbent’s morphology and surface 17 
chemistry. In this study, the behaviour of a cellulose nanofiber ion exchange sorbent 18 
derivatised with quaternary (Q) amine ligands at defined densities is characterised to 19 
address this. This material was selected as it has a large accessible surface area for viral 20 
particles and rapid process times. 21 
Initially the impact of surface chemistry on infective product recovery using low (440 22 
µmol/g), medium (750 µmol/g) and high (1029 µmol/g) ligand densities is studied. At 23 
higher densities product stability is reduced, this effect increased with prolonged adsorption 24 
durations of 24 minutes with just ~10% loss at low ligand density vs. ~50% at high. This 25 
could be mitigated by using a high flowrate to reduce the cycle time to ~1 minute. Next the 26 
impact of ligand density on the separation’s resolution was evaluated. Key to understanding 27 
virus quality is the virus particle: infectious virus particle ratio. It was found this parameter 28 
could be manipulated using ligand density and elution strategy. Together this provides a 29 
basis for viral vector separations that allows for their typically low titres and labile nature by 30 
using high liquid velocity to minimise both load and on-column times while separating key 31 




Nanofibers, anion exchange chromatography, viral vectors, downstream processing 34 
Introduction 35 
The adenovirus serotype 5 (Ad5) particle is a non-enveloped, icosahedral capsid with a 90-36 
100 nm diameter that carries a linear, double-stranded DNA genome (San Martin, 2012). 37 
Human Ad5 is the most widely studied adenovirus serotype and is a typical model for viral 38 
vector process development (Crystal, 2014). Ad5 is an attractive gene delivery vector due to 39 
structural stability, ability to carry large transgene payloads and broad tissue tropism 40 
(Crystal, 2014). As of 2017, 20% of all gene therapy trials utilise an adenovirus vector (Lee 41 
et al., 2017). In the majority of these clinical trials the Ad5 vector fulfils two roles; in an 42 
oncolytic capacity for treatment of cancers and as a vaccine whereby the vector expresses a 43 
foreign antigenic protein (Keeler, ElMallah, & Flotte, 2017). 44 
Downstream processing of viral vectors represents a significant bottleneck and a primary 45 
cost of production (Vellinga et al., 2014). Conventionally, industry and academia have 46 
relied heavily on the ultracentrifugation technique for downstream purification of highly 47 
purified viral vectors (Chen, Marino, & Ho, 2016). However, the process has major 48 
drawbacks including poor scalability and high operating costs (Vicente, Roldão, Peixoto, 49 
Carrondo, & Alves, 2011). 50 
Initial efforts to develop scalable purification platforms led to the repurposing of anion-51 
exchange resins designed for protein purification, building on experience of therapeutic 52 
protein processes. Increases in the physical size and complexity of biological products such 53 
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as viral vectors highlight the limitations of these conventional resin-based chromatographic 54 
platforms, for instance poor recovery of the complex biotherapeutics (Lucero et al., 2017).  55 
To address this, a number of alternative chromatography materials have been applied to the 56 
purification of viruses designed to improve the efficiency and scalability of the process. 57 
Monoliths have been applied to Ad5 purification (Whitfield, Battom, Barut, Gilham, & Ball, 58 
2009) as well as the separation of much larger enveloped virus species including Vaccinia 59 
viruses (350 nm) (Vincent et al., 2017). The recovery of a recombinant Ad5 gene therapy 60 
was improved from 28% using a Q-Sepharose™ XL column to 35% using a monolith 61 
column (CIM™ QA-1) (Lucero et al., 2017). Previous reports showed that the CIM™ QA-1 62 
was preferable over the weak anion CIM™ DEAE-1. The final infective coefficient of virus 63 
particle per infective virus particles (VP/IVP) was 13, a range documented as acceptable for 64 
potency by the Food and Drug Administration (Kramberger, Urbas, & Štrancar, 2015). 65 
Other work using a porous cast membrane Peixoto, Ferreira, Sousa, Carrondo, and Alves 66 
(2008) achieved a 62% recovery (determined by cell fluorescence) of infectious Ad5. As 67 
well as exploration of alternate adsorbents there has also been a significant amount of work 68 
to optimise process and platform design. Piergiuseppe Nestola et al. (2014) described 69 
purification of Ad5 using a two column, quasi-continuous, simulated moving-bed size 70 
exclusion chromatography (SEC) process which achieved a recovery of 86% determined by 71 
real-time PCR. 72 
In the this work nanofibers adsorbents are used which have seen a variety of separation 73 
applications and can be synthesised in a range of materials such as nylon (Stanelle, M 74 
Straut, & Marcus, 2007), glass and cellulose (Ruckenstein & Guo, 2004). The cellulose 75 
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nanofiber based adsorbents used exhibit a number of physical properties which could be 76 
beneficial for Ad5 purification when compared to existing commercial 77 
monolith/resin/membranes, including their high surface area and mobile phase accessibility 78 
to the entire functionalised surface. Ryu, Kim, Lee, Park, and Lee (2003) reported surface 79 




for nylon 6 nanofibers and poly(4-vinylpyridine)
 
nanofibers were shown to 80 




(Matsumoto, Wakamatsu, Minagawa, & Tanioka, 2006). Porous 81 





a surface significantly lower than nanofibers (Wang, Faber, & Ulbricht, 2009). Beaded 83 





Chang-Hung, Ruoh-Chyu, & Keh-Ying, 1995). Despite the high surface area of these resins, 85 
the pore size (typically less than 100 nm) results in size exclusion of Ad5 from the inner 86 
functionalised surface resulting in lower binding capacities (Lusky, 2005) for large 87 
biological product such as viruses than would otherwise be expected. The electrospinning 88 
process that is used to fabricate the nanofibers requires controlled atmospheric conditions in 89 
order to generate consistent nanofiber deposition. Using this approach an average nanofiber 90 
diameter within 5% of 350 nm (Hardick, Stevens, & Bracewell, 2011) can be achieved. The 91 
fibres are randomly deposited (non-woven) to create a consistent stationary phase 92 
architecture to avoid channelling while keeping favourable pressure and flow characteristics 93 
(Hardick et al., 2011). The resulting adsorbent bed once derivatised with an appropriate 94 
ligand and packed has convective mass transfer characteristics, and an internal porosity 95 
estimated to be 0.62 by mass-density-volume calculations. In this work the nanofibers are 96 
packed in a ~0.125 mL bed (height 0.3 mm, diameter 25 mm) (Hardick, Dods, Stevens, & 97 
Bracewell, 2013).  98 
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To create nanofibers with the desired separation properties for this use ligand density on the 99 
adsorbents is critical. Vicente, Fáber, Alves, Carrondo, and Mota (2011) demonstrated this 100 
parameter impacted recombinant baculovirus (rBV) product quality and impurity clearance 101 
for anion exchange membranes. P. Nestola et al. (2014) have shown on similar adsorbents 102 
that Ad5 recovery is doubled by reducing the grafted ligand density. In the current study, 103 
nanofibers incorporating Q amine ligands at low, medium and high densities on the 104 
adsorbent surfaces are used. It is hypothesised that modifying the density of the ligand in 105 
this manner would affect Ad5 binding and separation of product and process related 106 
impurities, as well as yield.  107 
Materials and Methods 108 
Materials  109 
The HEK293 cell line used for the generation of Ad5 stocks and for performing the β-110 
galactosidase infectivity titre were purchased from American Tissue Culture Collection 111 
(Manassas, VA, USA). Ad5containing a β-galactosidase gene insert were kindly gifted from 112 
the Clinical BioManufacturing Facility (Oxford, UK). Nanofiber adsorbents were made to a 113 
range of Q amine ligand densities of low (440 µmol/g), medium (750 µmol/g) and high 114 
(1029 µmol/g) quaternary (Q) ligand density nanofibers by Puridify (now GE Healthcare, 115 
Stevenage, UK). All chemicals were purchased from Sigma-Aldrich (Poole, UK) unless 116 
otherwise stated. Antibodies for Western blotting analyses were purchased from Abcam or 117 
2BScientific. Polyclonal antibody - Primary antibody: Rabbit polyclonal antibody to Ad5 118 
(catalogue number: ab6982, Abcam, Cambridge, UK), secondary antibody: Goat polyclonal 119 
antibody to rabbit IgG (catalogue number: ab6721, Abcam, Cambridge, UK). Ad5 Hexon 120 
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antibody - Mouse monoclonal antibody to Ad5 Hexon (catalogue number: 10R-8460 121 
2BScientific Limited, Upper Heyford, UK), secondary antibody: Rabbit polyclonal antibody 122 
to mouse IgG (catalogue number: ab6728, Abcam, Cambridge, UK).  123 
Methods 124 
HEK293 Cell Culture  125 
HEK293 cells were cultured in an incubator at 37°C in a 5% (v/v) CO2
 
enriched atmosphere 126 
at 95% humidity. Cells were cultured for three days and passaged at 80% confluency. Cells 127 
were counted using a haemocytometer and they were cultured in Dulbecco's Modified 128 
Eagle's Medium from Life Technologies (catalogue no: 21969035, Paisley, UK) 129 
supplemented with 10% (v/v) foetal bovine serum (Sigma-Aldrich, Steinheim, Germany), 130 
1% (v/v) penicillin/streptomycin (Life Technologies, Paisley, UK), and 2 mM L-glutamine 131 
(Biochrom, Cambridge, UK). Cells were cultured in 10-tiered HYPERFlasks
® 
(Sigma-132 
Aldrich, Steinheim, Germany). 133 
Adenovirus 5 Propagation in HEK293 Cells 134 
Infection of HEK293 cells with Ad5 was performed by adding 100 μL, 5.1 x 10
9
 VP of Ad5 135 
in 2.5% glycerol to HYPERFlasks
®
 containing HEK293 cells at 80% confluency. The cells 136 
were then incubated for 48 h in the cell culture incubator at 37°C, 5% (v/v) CO2 and 95% 137 
humidity. 138 
Adenovirus 5 Harvest and Clarification 139 
To harvest Ad5 propagated in HEK293 cells, the HYPERFlasks
® 
were knocked, removing 140 
the cells from culture surface, and the contents transferred to 50 mL centrifuge tubes. Cells 141 
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were stored on dry ice for 30 min and thawed at 37°C for 40 min. The cycle of freezing and 142 
thawing was performed three times to disrupt the cell membrane (Lucero et al., 2017). The 143 
cell lysate was then centrifuged at 2,000 rpm for 10 min, and filtered using 33 mm 144 
Polyethersulfone (PES) membrane sterile syringe driven filters (0.45µm, Merck Millipore, 145 
Feltham, UK) and pooled. Tangential flow filtration (TFF) of the clarified cell lysate (CCL) 146 
was conducted on a KR2i system using a 500 kDa molecular weight cut off (MWCO) D06-147 
E500-05-N hollow fiber (length 65 cm, surface area 370 cm
2
; both Spectrum Labs, Breda, 148 
The Netherlands) at a flow rate of 20 mL/min and transmembrane pressure of 2 Psi (± 0.5). 149 
The cell lysate was concentrated 4X and dialysed in binding buffer (20 mM Tris, pH 7.4) 150 
5X volume of retentate, sample was then diluted 1 in 4 to original harvest volume to control 151 
for changes in loading volume when comparing TFF and CCL feed. 152 
Scanning Electron Microscopy Analysis of Adenovirus 5 Binding to Quaternary 153 
Amine Functionalised Nanofibers  154 
Quaternary amine functionalised nanofiber disks were washed with ddH2O and submerged 155 
in an aqueous binding buffer containing 20 mM Tris pH 7.4. The nanofibers were then 156 
conditioned in fresh binding buffer for 30 min. Clarified Ad5 (~10
9 
VP: 100 μL) in culture 157 
media was added to 900 μL fresh binding buffer to which the discs were submerged and 158 
agitated at room temperature for 60 min. A selection from this sample of nanofiber disks 159 
were washed in binding buffer to remove non-bound material and submerged in 1% (v/v) 160 
glutaraldehyde solution for 10 seconds and left to dry at room temperature. A second batch 161 
of nanofiber disks were prepared as before and then submerged in 20 mM Tris, 1 M NaCl 162 
pH 7.4 for 5 minutes, the nanofibers were then washed with ddH2O and submerged in 1% 163 
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(v/v) glutaraldehyde aqueous solution for 10 s and dried at room temperature. Scanning 164 
electron microscopy (SEM) was used to image the virus particles bound the adsorbent, the 165 
open structure of nanofibers meant that no manipulation of the nanofiber bed was required 166 
to visualise adsorbent surface. Nanofibers were mounted on aluminium stubs using adhesive 167 
carbon taps. Mounted samples were coated in a 2 nm layer of gold/palladium using a 681 168 
Gatan ion beam coater (Roper Industries, Abingdon UK) and imaged using a JEOL 7401 169 
FEGSEM (JEOL, Peabody, MA US). 170 
Chromatography 171 
Two different Ad5 containing feeds were assessed to determine if a reduction in process 172 
impurities achieved by incorporating a TFF step into the process would change the feed 173 
binding characteristics on nanofiber membranes. Two feeds were prepared. One a cell lysate 174 
clarified by 33 mm Polyethersulfone (PES) membrane sterile syringe driven filters (0.45µm, 175 
Merck Millipore, Feltham, UK), referred to as clarified cell lysate (CCL). The second feed 176 
was prepared taking CCL then processed using TFF, referred to as ‘TFF’. Experiments were 177 
performed using an ÄKTA Avant (GE Healthcare Life Sciences, Buckinghamshire UK), 178 
with online measurements of pH, conductivity and UV absorbance (260 and 280 nm). The 179 
~0.125 mL nanofiber adsorbent (bed height 0.3 mm, diameter 25 mm) was equilibrated with 180 
10 mL wash buffer containing 20 mM Tris, pH 7.4 at a flow rate of 10 mL/min. 5 mL Ad5 181 
feed at a concentration of ~10
8
 filled virions per mL (VP/mL) was loaded onto the nanofiber 182 
adsorbent that was washed with binding buffer until conductivity reached a constant 183 
reading. A linear 20 mL gradient elution (20 mM Tris, 1 M NaCl, pH 7.4) was applied to 184 
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nanofibers at a flow rate of 10 mL/min to elute Ad5 bound to the nanofiber adsorbent. The 185 
nanofiber adsorbent was washed with 2 M NaCl 20 mM Tris, pH 7.4.  186 
To investigate the effect of prolonged adsorption durations on Ad5, 5 mL of CCL was 187 
loaded onto the nanofiber and wash steps were performed with 10, 40, 80 or 240 mL 188 
equilibration buffer at a flow rate of 10 mL/min. Peak resolution was determined by 189 
identifying peaks from 20 mL gradient elutions and a step elution methodology was 190 
developed using the relative salt concentrations identified.  191 
The resolution of peaks was refined by extending the gradient elutions when multiple peaks 192 
with similar isoelectric points were identified. Total run time for step elution was limited, 193 
whilst maintaining a constant flow rate of 10 mL/min, to minimise any potential effects of 194 
prolonged adsorption durations on Ad5 infective recovery whilst allowing high resolution 195 
separations. Elution fractions were collected using a F9-R fraction collector (GE Healthcare 196 
Life Sciences, Buckinghamshire UK). All samples were diluted 1 in 7.5 in phosphate 197 
buffered saline to minimise the effects of high salt on recovery of infective Ad5 particles. 198 
Western Blotting 199 
Fractions were concentrated using Vivaspin
®
 Turbo 4 (Sartorius, Gottingen Germany). 200 
Total protein was quantified using the Modified Lowry protein assay according to 201 
manufacturer’s instructions (ThermoFischer, East Grinstead, UK). Protein samples were 202 
treated 1:1 with Laemmli sample treatment buffer: 50 mM Tris-HCl, 4% (w/v) SDS 203 
(Sigma), 10% (v/v) β-mercaptoethanol (Sigma), 20% (v/v) glycerol (Sigma), a trace of 204 
Coomassie brilliant blue R (Sigma), pH 6.8, and heated at 95°C for 5 min. Proteins were 205 
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separated via SDS-PAGE using NuPAGE™ precast 10%, BisTris mini-gels 206 
(ThermoFischer, East Grinstead, UK) with gels run at 100 V per gel. Proteins were 207 
transferred from gels to polyvinylidine difluoride membranes using an iBlot™ 2 gel transfer 208 
device following the manufacturer’s instructions. Blots were blocked with 5% milk (w/v) 209 
for 1 h at room temperature before they were incubated in primary antibody (mouse 210 
monoclonal antibody to Ad5 hexon in 2% milk (w/v)) overnight at +4°C. Blots were 211 
washed three times in 1X tris buffered saline-tween (TBS-T) for 5 min before incubating in 212 
secondary antibody (rabbit polyclonal antibody to mouse IgG (HRP-conjugated) in 2% 213 
milk) for 2 h at room temperature. Blots were imaged after a 1 min incubation in enhanced 214 
chemiluminescent reagent using an Amersham Imager 600 (GE Healthcare Life Sciences, 215 
Buckinghamshire UK).  216 
Analysis of Purified Adenovirus 5 using Transmission Electron Microscopy 217 
Transmission electron microscopy was used to visualise Ad5. To perform the analysis, Ad5 218 
particles were negatively stained by adding uranyl acetate to Ad5 samples. The stained 219 
samples were dropped onto a carbon grid (400 mesh) and loaded onto JEOL 1010 220 
Transmission Electron Microscope (JEOL, Peabody, MA USA) before they were imaged. 221 
Host Cell Protein Quantification 222 
Host cell protein (HCP) concentrations from purified Ad5 fractions were analysed using the 223 
HEK293 HCP ELISA kit F650R (Cygnus Technologies, Southport, NC, USA) following 224 
manufacturer’s instructions.  225 
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Quantitative PCR 226 
To assess total Ad5 capsids containing DNA, samples were analysed using Adeno-X™ 227 
Rapid Titer Kit (Takara Bio Europe, Saint-Germain-en-Laye, France). Briefly, samples 228 
were pre-treated with DNAase to remove ex-virus DNA, and then chemically lysed with 229 
protease; DNA was isolated using NucleoSpin® Virus Columns (Takara Bio Europe, Saint-230 
Germain-en-Laye, France). Samples were added to master reaction mix in a 96 well plate so 231 
that each well contained 2 µL of unknown sample or standard control DNA, 6.8 µL PCR-232 
grade H2O, 0.4 µL Adeno-X forward primer (10 µM), 0.4 µL Adeno-X reverse primer (10 233 
µM), 0.4 µL ROX™ Reference Dye LMP, 10.0 µL SYBR® Advantage qPCR Premix. All 234 
reaction were performed using a CFX Connect™ Real-Time PCR Detection System 235 
(Applied Biosystems, CA, USA) using the following cycle conditions: stage one, 95°C for 236 
30 seconds; stage two, 95°C for 5 seconds, followed by 60°C for 30 seconds (40 237 
repetitions); stage three, dissociation curve of 95°C for 10 seconds, 65°C to 95°C increment 238 
0.5°C every 5 seconds. To ensure that recoveries obtained from NucleoSpin® Virus 239 
Columns (Takara Bio Europe, Saint-Germain-en-Laye, France) were not affected by the 240 
range of salt conditions present in the elution samples, a range of samples containing 241 
standard control DNA containing 20 mM Tris, and a range of salt concentrations from 0-0.5 242 
M NaCl (all pH 7.4) were also analysed.  243 
Adenovirus 5 Cell Infectivity Assay  244 
The detection and quantification of Ad5 units that were able to deliver the β-galactosidase 245 
gene were analysed as a measure of sample infectivity using the β-galactosidase reporter 246 
gene staining kit (Sigma-Aldrich, Taufkirchen Germany). Reactions were conducted 247 
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following manufacturer’s instructions but they were modified for a 96-well plate format. 248 
Briefly, plates were coated in poly-L-lysine for 10 min. HEK293 cell suspension of 249 
concentration of 4 x 10
5
 cells per mL were loaded per well and incubated overnight. Growth 250 
media was removed from wells prior to transfection with serial dilutions of Ad5 (100 µL of 251 
Ad5 sample in supplemented DMEM) and the plate incubated for 1 h at 37°C. The Ad5 252 
sample was then removed from wells, replaced with 100 µL of growth media and the plate 253 
was incubated overnight at 37°C. To stain, media was removed from wells and cells 254 
(attached to well surfaces) were washed twice with phosphate buffered saline (PBS), fixed 255 
with 1X fixation buffer (20% formaldehyde, 2% glutaraldehyde in 10X PBS) and incubated 256 
for 10 min at room temperature. Wells were washed twice with PBS followed by 30 µL of 257 
staining solution. Plates were incubated at 37°C for 24 h and blue stained cells were 258 
manually counted using a light microscope. 259 
Results and Discussion  260 
Binding and Elution of Adenovirus 5 under Batch Conditions 261 
Batch experiments were conducted to gain insight into the mechanism for virus binding with 262 
the purification materials (Wickramasinghe, Carlson, Teske, Hubbuch, & Ulbricht, 2006). 263 
Direct imaging of bound virus particles was conducted using scanning electron microscopy 264 
(SEM) to determine if the binding and elution interaction behaved as expected using 265 
previously described buffer conditions (Peixoto et al., 2008). Adenovirus 5 particles were 266 
bound to anion exchange nanofibers under batch conditions by submerging nanofiber disks 267 
into binding buffer containing the virus. The nanofibers were then imaged using SEM 268 
(Figure 1). Adenovirus 5 virions measure ~90 nm in diameter and are clearly visible bound 269 
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to the nanofiber adsorbent. Other host cell components are also visible as a layer bound to 270 
the nanofiber surface. To determine if product and impurity components had migrated into 271 
the inner bed structure as expected several cross sections through the nanofiber bed were 272 
imaged with no observable differences between layers (data not shown). To elute the bound 273 
virus, nanofibers were submerged in high salt (1 M NaCl, 20 mM Tris, pH 7.4) elution 274 
buffer subsequent SEM reveals all components were visibly removed from the nanofiber 275 
surface (Figure 1).  276 
Comparison of Clarified and Buffer Dialysed Adenovirus 5 Feeds 277 
Adenovirus 5 harvest was clarified with 0.45 µm filters, this clarified cell lysate (CCL) was 278 
divided - 50% was further processed using ultrafiltration and diafiltration (UF–DF) with a 279 
500 kDa TFF system to retain Ad5 and remove bulk host cell impurities before dialysis into 280 
binding buffer. The TFF and CCL feeds were analysed using the β-galactosidase infectivity 281 
assay to characterise the effect of processing on Ad5 infective potency. After TFF filtration 282 
the retentate had an infective recovery of 89% compared to the CCL.  283 
A 5 mL (5.6 x 10
8
 ± 5.6 x 10
7
 IVP) volume of CCL Ad5 feed was loaded onto a 0.125 mL 284 
anion exchange nanofiber adsorbent at 10 mL/min (Figure 2), and a 20 mL gradient elution 285 
of up to 1 M NaCl was applied to the column. The elution profile was then compared to a 5 286 
mL (5.6 x 10
8
 ± 5.6 x 10
7
 IVP) load of TFF feed under the same process conditions. This 287 
was repeated for low, medium and high density Q amine ligand nanofibers. A large flow 288 
through peak was observed for all the ligand densities when challenged with CCL feed. This 289 
was not observed for the TFF feed, due to the removal of impurities during the TFF step. 290 
The total UV peak area for the TFF feed is reduced compared to the CCL feed, again due to 291 
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clearance of host cell impurities. Comparison of the CCL feed across the three different Q 292 
amine nanofibers (low, medium and high ligand density) shows elution profiles are distinct 293 
across all three fiber types (Figure 2), with components binding more tightly giving rise to 294 
more peaks and requiring higher ionic strength to elute as ligand density increases. There 295 
are more subtle differences seen for the TFF treated material, which are more noticeable at 296 
the highest charge density. An explanation could be that with the reduced impurity levels 297 
present in the TFF material interactions between Ad5, impurities and the charge surface that 298 
allow discrimination for the CCL material are reduced. The distinct elution profile across 299 
the three fiber types, demonstrate different separation capabilities of nanofibers as the Q 300 
amine ligand density changes. This suggests that by tailoring the ligand functionalisation of 301 
the nanofibers it is possible to optimise Ad5 purification process for improved separations. 302 
Extended Adsorption Periods on Quaternary Amine Functionalised Nanofibers 303 
Reduce Adenovirus 5 Infectivity 304 
Poor viral vector recoveries over an ion exchange chromatography step have been attributed 305 
to prolonged adsorption periods that cause degradation of capsid integrity and entrapment of 306 
virus particles in the complex internal adsorbent structures (Trilisky & Lenhoff, 2009). 307 
Hardick et al. (2013) showed that the large inter-fiber space and morphology of the 308 
functionalised surface of nanofibers minimises diffusive mass transfer limitations, a 309 
property which has been shown to be detrimental to capacity and recovery of large 310 
biotherapeutic molecules (Wickramasinghe et al., 2006). This open structure (Figure 1) may 311 
minimise entrapment events and multipoint attachment, suggesting loss in infective units is 312 
a result of irreversible binding or capsid damage. 313 
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The effects of prolonged binding duration on the recovery of infective Ad5 (Figure 3) was 314 
analysed. CCL clarified Ad5 feed (5 mL) was loaded onto nanofiber columns and 315 
adsorption durations were selected to approximately replicate binding durations of current 316 
chromatographic viral vector manufacturing processes. Figure 4 shows overlay 317 
chromatograms for low ligand density 1, 4, 8 and 24 min adsorption periods. A 100% 318 
recovery of infective virus was observed after the shortest binding duration (1 min) using 319 
low ligand density nanofibers (Figure 3). Extending binding durations from 4-24 min using 320 
low ligand density nanofibers did not cause a significant decrease in the infectivity of Ad5 321 
eluate, with recoveries between 87-90%. At an extended adsorption duration of 24 min there 322 
was a dramatic loss of almost 50% in total infective capsids for medium and high ligand 323 
density nanofibers. Significant losses in Ad5 infective recoveries were also observed on 324 
high ligand density nanofibers after adsorption periods of 1-8 min and 8-24 min adsorption 325 
periods.  326 
The substantial losses in Ad5 infectivity observed with use of the medium and high ligand 327 
density nanofibers indicates product damage. This could be a result of loss of critical 328 
features of the virus for its infectivity, i.e. fiber proteins (McNally, Darling, Farzaneh, 329 
Levison, & Slater, 2014). Alternatively the loss of infective units could be caused due to 330 
deformation of the capsid as it is ‘pulled’ onto the functionalised surface over the adsorption 331 
duration, damaging the capsid. Similar effects have been observed during the recovery of 332 
virus-like particles of recombinant hepatitis B virus surface antigen (Huang et al., 2006). 333 
This is of particular relevance for Ad5 as Perez-Berna et al. (2012) have shown that the 334 
virus maturation process gives rise to a metastable structure. These brittle capsids may show 335 
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a reduced resistance to multipoint attachment, when compared to immature non-infective 336 
Ad5. These data suggest that although medium and high ligand density nanofibers limit the 337 
recovery of infective Ad5 over extended adsorption periods, acceptable recovery can be 338 
achieved if the rapid bind/elute times possible with these nanofiber adsorbents is utilised. 339 
Quaternary Amine Functionalised Nanofibers Achieve Efficient, High Yield 340 
Purification of Infectious Adenovirus 5 Particles 341 
Vicente, Fáber, et al. (2011) reported that ligand density caused a larger change in binding 342 
capacity for a protein (bovine serum albumin) when compared to either a phage (rBV) or 343 
virus (Ad5). To investigate whether an impact could be seen on Q functionalised nanofibers 344 
three ligand densities were exposed to a greater vector load challenge. Here the nanofiber 345 
column volume (CV) 0.125 mL, was loaded with 50 mL (400 CV) TFF processed Ad5 feed 346 
(total load 2.39 x 10
10 
VP, 5.6 x 10
9 
IVP) (Figure 5). Five 10 mL flowthrough fractions were 347 
collected from each run and screened for the presence of infective Ad5 capsids. No infective 348 
Ad5 capsids were present in the flowthrough (data not shown) which indicates that capacity 349 
was not reached. Therefore we performed a Fermi estimate to understand what the limit of 350 
capacity for viral particles this nanofiber adsorbent system is likely to be capable of. Based 351 
on the SEM image (Figure 1) it was conservatively assumed 25 viral particles are bound per 352 
micron of nanofiber and calculating in the region of 5,000 km of nanofiber to be present in a 353 
1 mL packed bed we determined a capacity 1.25 x 10
14
 VP/mL. The load challenge of 1.78 354 
x 10
11
 VP/mL used in this study is far lower than this calculated capacity and exceeds what 355 
we were able to test in this study. Indeed in such a low titre vector manufacturing process 356 
the dynamic binding capacity (DBC) would likely not be reached as many 1,000s of CVs 357 
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would be required, even when considering the contribution of impurity binding in a well-358 
designed ion exchange step. 359 




 virus particles (VP) per dose 360 
depending on the therapy and site of administration (Habib et al., 2001; Smaill et al., 2013). 361 
Whilst further work to determine the upper limit of capacity is required at the current scale, 362 
a single 0.125 mL column can recover ten 10
9
 VP doses per cycle. Operating at 10 mL/min 363 
(4,800 CV/h), a conservative flowrate for this adsorbent with an 80 mL full cycle, the 364 
nanofibers exhibit a productivity of 1.43 x 10
15 
VP/L/h. In comparison a 1 mL Sepharose Q 365 
XL column operating at 0.5 mL/min was shown to have an Ad5 DBC of 1.30 x 10
11 
VP by 366 
Bo et al. (2015) which gives rise to a productivity of 4.88 x 10
13
 VP/L/h. Under these 367 
assumptions nanofibers exhibit a 29-fold increase in productivity compared to conventional 368 
packed bed resins.  369 
This compares favourably with Hardick, Dods, Stevens, and Bracewell (2015) where it is 370 
shown nanofibers are capable of operating at high flow rates to increase protein purification 371 
productivity, achieving a 15-fold increase compared to packed bed adsorbents. Running the 372 
Ad5 separation at this higher velocity (70 mL/min) shows no significant impact on Ad5 373 
infective recovery (data not shown). Operating under these conditions nanofibers could 374 
achieve a productivity of 1 x 10
16
 VP/L/h.  375 
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Reproducibility and Life Cycle Performance of Quaternary Amine Functionalised 376 
Nanofibers  377 
High performance and reproducible performance of chromatography tools are paramount in 378 
bioprocessing (Rathore & Sofer, 2005). Nine consecutive bind/elute profiles for each 379 
nanofiber ligand density were compared to demonstrate operational reproducibility. There 380 
was no detectable loss in binding capacity after nine runs across all three nanofiber ligand 381 
densities suggesting a 2 M NaCl wash was sufficient to remove TFF Ad5 feed components 382 
between runs (data not shown). The absorbance flow profiles were then compared to two 383 
more nanofiber cartridges of the same chemistry to demonstrate manufacturing 384 
reproducibility. Peak area variability of <5% was observed between cartridges suggesting 385 
good manufacturing reproducibility (data not shown).  386 
Separation of Infectious Adenovirus 5 Particles Using Quaternary Amine 387 
Functionalised Nanofibers  388 
High infective product recovery is the primary challenge when purifying a viral vector. It is 389 
necessary to assess both the total recovery of Ad5 capsids and their infective potency across 390 
each unit operation. In Table I, this data is presented for each of the ligand densities (Figure 391 
6). Quantitative PCR analysis was used to determine the recovery of total Ad5 VP. At low 392 
ligand density fraction LP4 contained the majority of VPs while at medium ligand density it 393 
was MP5 and at high ligand density fraction HP6 was found to contain most of the virus 394 
particles. TEM analysis was used confirm presence of Ad5 (Figure 7). This increase in 395 
fraction number for VP elution with ligand density is anticipated and reflects the 396 
chromatograms seen in Figure 6. 397 
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Adenovirus 5 particle infectivity was measured by counting β-galactosidase staining in 398 
infected cells (Table I). The ratio of viral particles to infective viral particles or units 399 
(VP/IVP) is often used as an indicator of product quality. At low ligand density the LP4 400 
fraction contained a ratio of 4.59 VP/IVP, MP5 had 5.12, and HP6 4.00 VP/IVP all are 401 
within accepted ranges for clinical use (Kramberger et al., 2015) and despite the different 402 
ligand densities presenting unique elution profiles with product eluting at different 403 
conductivities, the highest titre peaks (LP4, MP5 and HP6) showed a relatively consistent 404 
infective ratio. The highest proportion of packed, non-infective Ad5 capsids were separated 405 
in HP7 using high ligand density nanofibers with a coefficient of 16.04 VP/IVP, suggesting 406 
clearance of a population of lower quality Ad5. Damaged or immature Ad5, represent 407 
important possible product related impurities. Therefore their separation is of particular 408 
interest for the manufacture of viral vectors for therapeutic use. 409 
Clearance of host cell proteins (HCPs) a process related impurity of primary importance in 410 
the manufacture of a therapeutic biological product is documented in Table 1. Removal 411 
across the TFF and chromatography step was high with >95% (compared to non-purified 412 
Ad5 feed) of HCPs removed.  413 
The mass balances of packed, infective Ad5 capsid recovery across all nanofibers ligand 414 
densities were similarly high (Table I) especially when compared to other membrane 415 
adsorbers (P. Nestola et al., 2014) and monoliths (Lucero et al., 2017) with recoveries of 416 
70%, and 34% respectively 417 
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Separation of Free Hexon Capsid Protein 418 
Analysis of capsid recovery provides evidence for the separation of free capsid proteins 419 
from assembled virus particles. Hexon is a key component within the Ad5 capsid (see 420 
Figure 1) but can also be found in non-assembled forms (Klyushnichenko, Bernier, Kamen, 421 
& Harmsen, 2001). It has been shown to be immunogenic and represents an important 422 
product related impurity (Bradley, Lynch, Iampietro, Borducchi, & Barouch, 2012). A 423 
western blot (Figure 8) was used to show the distribution of hexon during the separations 424 
shown in Figure 6. Hexon was identified in the purified fractions, LP3, LP4, MP5, and HP6, 425 
demonstrated to contain packed and infective Ad5 capsids. Hexon is also found in MP3 and 426 
HP4 fractions that do not contain infective Ad5 particles and therefore is free hexon protein 427 
that is not incorporated into complete capsids. This suggests with medium and high ligand 428 
density nanofibers it was possible to isolate free hexon from capsid bound hexon, it is 429 
possible at low ligand density free capsid does not bind and goes straight into the flow 430 
through. The ability to resolve free hexon from an adenovirus feed using a DEAE-Fractogel 431 
anion exchange was also demonstrated by Green et al. (2002), eluting, as shown here at low 432 
ionic strength (<25 mS/cm).  433 
Conclusions  434 
Nanofibers provide a promising scalable capture platform by which to purify Ad5 from 435 
HCP and free hexon, producing an enriched product pool with a high product quality as 436 
determined by the VP/IVP ratio. Using medium and high ligand density nanofibers it was 437 
possible to achieve a separation of product peaks from a hexon rich peak during salt 438 
gradient elution. The Ad5 hexon forms the major building block of the virus capsid (>60%) 439 
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(Perez-Berna et al., 2012) and non-assembled hexon represents major product impurity due 440 
to its antigenic properties. We show that nanofiber materials allow very high infective 441 
recoveries of >90%. Critical to this is adsorption time, which when reduced from 24 to 8 442 
min improved recovery from ~50% to >90% and up to 97% for 1 min. The macroporosity, 443 
convective mass transfer characteristics and shallow bed height of the nanofibers allows for 444 
rapid separations in this manner. Operating under these conditions a 29-fold productivity 445 
improvement can be achieved over a classical beaded packed bed resin process. The high 446 
recovery achieved across this initial capture step allows for a two or three step 447 
chromatography process to readily be considered to meet a given product’s specification. 448 
The results presented here therefore demonstrate potential clinical utility of this nanofiber 449 
adsorbent as a high productivity manufacturing technology for the capture of infective Ad5.  450 
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Table I. The total recoveries of infective Ad5 units (IVP, analysed by β-Gal stain), DNA containing (VP, analysed by qPCR) Ad5 units and the 461 
ratio of these two populations within all Ad5 containing peaks separated on low (440 µmol/g), medium (750 µmol/g) and high (1029 µmol/g) Q 462 
ligand density nanofibers. No qPCR signal was detected for samples LP3 and MP4. Good amounts of host cell protein was shown to be removed 463 























































 CCL Total 6.31E+08 9.40E+06 - - - - - - - N/A 1.30E+06 0% 
 Feed (TFF) Total 5.60E+08 8.70E+06 100.0% 1.53% 2.39E+09 3.30E+07 100.0% 1.31% 4.23 N/A 3.56E+05 72.6% 




- 0.29 3.82E+04 97.1% 




4.59 0.49 4.00E+04 96.9% 




4.57 1 4.87E+04 96.3% 
   Total 5.07E+08   90.2% 3.81% 2.27E+09   94.8% 3.38% 4.47   4.23E+04 96.8% 




- 0.43 6.28E+04 95.2% 




5.12 0.6 3.67E+04 97.2% 




8.25 1 6.05E+04 95.4% 
   Total 5.14E+08   91.4% 4.81% 2.53E+09   105.4% 11.91% 4.93   5.33E+04 95.9% 




4.00 0.61 3.32E+04 97.5% 




16.04 1 5.45E+04 95.8% 






Figure 1. Top - Scanning electron microscopy images of Ad5 bound to Q ligand and eluted 468 
from functionalised nanofibers. Bottom – Diagram of adenovirus proteins, highlighting the 469 
level of complexity within each virion (diagram combined from Mangel and San Martin 470 
(2014); San Martin (2012)). Adenovirus proteins prefixed with a ‘p’ denote proteins that 471 
undergo proteolysis by adenovirus maturation protein (AVP) as part of a maturation which 472 
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causes a disassociation of the adenovirus genome from the capsid and a capsid stiffening, 473 
priming the capsid for uncoating under endosomal acidification.  474 




Figure 2. Elution profile comparison of Ad5 on low (440 µmol/g), medium (750 µmol/g) 477 
and high (1029 µmol/g) Q ligand density nanofibers (CV = 0.125 mL). Ad5 was separated 478 
from a clarified cell lysate (CCL) and a tangential flow filtration (TFF) UF–DF 500 kDa 479 
retentate diafiltered into binding buffer (20 mM Tris, pH 7.4). Loads (5 mL) of both Ad5 480 
feeds containing a total load of 5.6 x 10
8
 ± 5.6 x 10
7
































































































generated using a 20 mL gradient elution at 10 mL/min from 0 M NaCl, 20 mM Tris pH 7.4, 482 
to 1 M NaCl, 20 mM Tris pH 7.4 (n=3). 483 




Figure 3. Recovery of adenovirus 5 infectivity during adsorption to nanofiber based ion 486 
exchangers, measured by a cell based β-galactosidase reporter assay. Low (440 µmol/g), 487 
medium (750 µmol/g) and high (1029 µmol/g) Q ligand density nanofibers (CV = 0.125 488 
mL) were loaded with 6.22 x 10
8
 IVP of Ad5 in a clarified feed (n=3). 489 






























Figure 4. Elution profile of four chromatography runs of clarified cell lysate Ad5 feed with 491 
varying wash durations (10, 40, 80, 240 mL or 1, 4, 8, 24 min) in triplicate for a total of 492 
twelve runs for Low (440 µmol/g) charge density.  493 
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Figure 5. High loadings of adenovirus feed material to quaternary amine exchange 496 
nanofibers. A 50 mL (high volume) TFF Ad5 feed (2.39 x 10
10 
VP, 5.6 x 10
9
 IVP) was 497 
























































































separated using low (440 µmol/g), medium (750 µmol/g) and high (1029 µmol/g) Q amine 498 
ligand density nanofibers (CV = 0.125 mL). Fiber saturation was not achieved (n=3).  499 




Figure 6. The impact of increasing Q amine ligand density on the resolution of Ad5 feed 502 
components. Elution peak profiles of low (440 µmol/g), medium (750 µmol/g) and high 503 
(1029 µmol/g) Q amine ligand density nanofibers were recorded from a chromatography run 504 
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of 5 mL (2.39 x 10
9 
VP, 5.6 x 10
8
 IVP) TFF feed loaded onto a 0.125 mL nanofiber column 505 
at a flow rate of 10 mL/min (n=3).  506 




Figure 7. High (A) and Low (B) magnification transmission electron microscopy analysis 509 
showed the presence of Ad5 particles in fraction HP6. 510 
 511 






Figure 8. Western blot using a Hexon antibody with a secondary antibody (rabbit polyclonal 514 
antibody) to mouse IgG (HRP-conjugated) showing Adenovirus 5 hexon expression in 515 
purified fractions from low (440 µmol/g), medium (750 µmol/g) and high (1029 µmol/g) Q 516 
ligand density nanofibers collected from step elution chromatograms (n=3). A molecular 517 
weight marker (MWM) and Ad5 from a clarified cell lysate (CCL) and a tangential flow 518 
filtration (TFF) UF–DF 500 kDa retentate diafiltered into binding buffer (20 mM Tris, pH 519 
7.4) was also loaded. 520 
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